{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:09:53Z","timestamp":1793531393006,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cpcardiol.2024.102664","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T12:14:43Z","timestamp":1716380083000},"page":"102664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data &amp; randomized clinical trials"],"prefix":"10.1016","volume":"49","author":[{"given":"Karan B.","family":"Bhanushali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-0314","authenticated-orcid":false,"given":"Heena K.","family":"Asnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambica","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102664_bib0001","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","article-title":"Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes","volume":"62","author":"Garg","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102664_bib0002","first-page":"e19379","article-title":"The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure","volume":"13","author":"Fadiran","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.822968","article-title":"SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial?","volume":"8","author":"Korosoglou","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102664_bib0004","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102664_bib0005","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102664_bib0006","article-title":"SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects","volume":"55","author":"Garofalo","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102664_bib0007","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102664_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.cpcardiol.2024.102664_bib0009","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102664_bib0010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cpcardiol.2024.102664_bib0011","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102664_bib0012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2024.102664_bib0013","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cpcardiol.2024.102664_bib0014","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cpcardiol.2024.102664_bib0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cpcardiol.2024.102664_bib0016","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.cpcardiol.2024.102664_bib0017","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2024.102664_bib0018","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2024.102664_bib0019","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102664_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"10365","key":"10.1016\/j.cpcardiol.2024.102664_bib0021","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0022","first-page":"1032","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure","volume":"107","author":"Joshi","year":"2021","journal-title":"Heart BMJ Publ Group"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0023","first-page":"632","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: a State-of-the-Art Review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102664_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102664_bib0025","first-page":"45","article-title":"Risks vs Benefits for SGLT2 Inhibitor Medications","volume":"35","author":"Pittampalli","year":"2018","journal-title":"Fed Pract"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102664_bib0026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102664_bib0027","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi","year":"2014","journal-title":"Diabetes Metab"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102664_bib0028","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/17425255.2017.1258055","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies","volume":"13","author":"Tsimihodimos","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102664_bib0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","article-title":"Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study","volume":"25","author":"St-Pierre","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0031","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: harms or Unexpected Benefits?","volume":"59","author":"Andreea","year":"2023","journal-title":"Medicina (Lithuania)"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.766125","article-title":"Safety of SGLT2 Inhibitors: a Pharmacovigilance Study from 2013 to 2021 Based on FAERS","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0033","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"The BMJ"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102664_bib0034","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG Outcome study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0035","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102664_bib0036","article-title":"SGLT2 inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2024.102664_bib0037","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","article-title":"Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems","volume":"27","author":"Raschi","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2024.102664_bib0038","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624003037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624003037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T01:46:38Z","timestamp":1722131198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624003037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0146280624003037"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102664","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3045247\/v1","asserted-by":"object"}]},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102664"}}